Corrigendum: Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma &lt;i&gt;via&lt;/i&gt; the combination therapy with FOXM1 inhibitor RCM1. This evidence concerns the gene TNNI3 and rhabdomyosarcoma.